The safety and efficacy of sertaconazole nitrate cream 2% for tinea pedis

Cutis

Volumn 78, Issue 4, 2006, Pages 268-274

  Savin, Ronald ^a   Jorizzo, Joseph ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; IMIDAZOLE DERIVATIVE; SERTACONAZOLE; THIOPHENE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MIDDLE AGED; MULTICENTER STUDY; OINTMENT; RANDOMIZED CONTROLLED TRIAL; TINEA PEDIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHILD; DOUBLE-BLIND METHOD; HUMANS; IMIDAZOLES; MIDDLE AGED; OINTMENTS; THIOPHENES; TINEA PEDIS; TREATMENT OUTCOME; UNITED STATES;

EID: 33750849572     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol. 1996;34:282-286.
2. Martin AG, Kobayashi GS. Superficial fungal infection: dermatophytosis, tinea nigra, piedra. In: Freedberg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York, NY: McGraw-Hill; 1999:2337-2357.
3. Bell-Syer SE, Hart R, Crawford F, et al. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev. 2002;(2):CD003584.
4. Caputo R, De Boulle K, Del Rosso J, et al. Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature. J Eur Acad Dermatol Venereol. 2001;15:512-316.
5. Noble SL, Forbes RC, Stamm PL. Diagnosis and management of common tinea infections. Am Fam Physician. 1998;58:163-178.
6. Seebacher C. The change of dermatophyte spectrum in dermatomycoses [in German]. Mycoses. 2003;46:42-46.
7. Kemna ME, Elewski BE. A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol. 1996;35:539-542.
8. Gupta AK, Chow M, Daniel CR, et al. Treatments of tinea pedis. Dermatol Clin. 2003;21:431-462.
9. Hainer BL. Dermatophyte infections. Am Fam Physician. 2003;67:101-108.
10. Crawford F, Hart R, Bell-Syer S, et al. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2000;(2):CD001434.
11. Getting rid of athlete's foot. Drug Ther Bull. 2002;40(7):53-54.
12. Palacín C. Sertaconazole: a pharmacological update. Prous Science. 2002:25-27.
13. Raga MM, Moreno-Manas M, Cuberes MR, et al. Synthesis and antimycotic activity of (benzo[b]thienyl)methyl ethers of 1-(2,4-dichlorophenyl)-2-(1H- imidazol-1-yl)-ethanol and of (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl) ethanone oxime. Arzneimittelforschung. 1992;42:691-694.
14. Drouhet E, Dupont B. In vitro antifungal activity of sertaconazole. Arzneimittelforschung. 1992;42:705-710.
15. Palacín C, Sacristán A, Ortiz JA. In vitro activity of sertaconazole. Arzneimittelforschung. 1992;42:699-705.
16. Prats G, Mirelis B. Actividad antibacteriana in vitro de sertaconazole. Rev Esp Quimioter. 1995;8:325-326.
17. Agut J, Palacín C, Sacristán A, et al. Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. Arzneimittelforschung. 1992;42:718-720.
18. Agut J, Palacín C, Salgado J, et al. Direct membrane-damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimittelforschung. 1992;42:721-724.
19. Farré M, Ugena B, Badenas JM, et al. Pharmacokinetics and tolerance of sertaconazole in man after repeated percutaneous administration. Arzneimittelforschung. 1992;42:752-754.
20. Agut J, Moren M, Rego M, et al. Pharmacokinetic evaluation of labelled sertaconazole after dermal application. Arzneimittelforschung. 1992;42:748-751.
21. US Food and Drug Administration. Guidance for industry: uncomplicated and complicated skin and skin structure infections - developing antimicrobial drugs for treatment. July 1998. Available at: http://www.fda.gov/cder/guidance/ 2566dft.pdf. Accessed Seprember 15, 2006.
22. Bedinghaus JM, Niedfeldt MW. Over-the-counter foor remedies. Am Fam Physician. 2001;64:791-796.
23. Crawford F. Athlete's foot. Clin Evid. Dec 2004:2266-2270.
24. Alomar C, Bassas S, Casas M, et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneimittelforschung. 1992;42:767-773.
25. Contet-Audonneau N, Viguié C, Guiguen C, et al. Comparison of the efficacy and tolerance of sertaconazole and sulconazole cream in patients suffering from cutaneous candidiasis and dermatophytosis: a double-blind, randomized, multicentric study. Paper presented at: 1994 Congress of the International Society for Human and Animal Mycology; March 13-18, 1994; Adelaide, Australia.
26. Fonseca E, del Pozo J, Márquez M, et al. Evaluación de la eficacia y seguridad de sertaconazole en crema en aplicación única diaria en el tratamiento de la dermatofitosis. Piel. 1997;12:183-188.
27. Carrillo-Muñoz AJ, Fernández-Torres B, Cárdenes DC, et al. In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility. Chemotherapy. 2003;49:248-251.